Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform

Japan’s health ministry is expected to expand the scope of products eligible for the price maintenance premium (PMP) for drugs that add innovative new indications and set a grace period of four years for a proposed rule to exclude previously...read more